← InSilico Medicine Cayman TopCo overview

InSilico Medicine Cayman TopCo vs Sichuan Kelun-Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InSilico Medicine Cayman TopCo (3696.HK)

Q2 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

June 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Latest
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Sichuan Kelun-Biotech (6990.HK)

Q3 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

August 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

Latest
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.